Exercise Intervention for Health Research Group (EXINH-RG), Department of Physiotherapy, Universitat de València, Valencia 46010, Spain.
Navarrabiomed, Navarra Hospital Complex (CHN), Public University of Navarra (UPNA), Navarra Medical Research Institute (IdiSNA), Pamplona 31008, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid 28029, Spain.
J Sport Health Sci. 2021 Dec;10(6):609-619. doi: 10.1016/j.jshs.2021.06.004. Epub 2021 Jun 29.
BACKGROUND: Cardiorespiratory fitness (CRF) is inversely associated with mortality in apparently healthy subjects and in some clinical populations, but evidence for the association between CRF and all-cause and/or cardiovascular disease (CVD) mortality in patients with established CVD is lacking. This study aimed to quantify this association. METHODS: We searched for prospective cohort studies that measured CRF with cardiopulmonary exercise testing in patients with CVD and that examined all-cause and CVD mortality with at least 6 months of follow-up. Pooled hazard ratios (HRs) were calculated using random-effect inverse-variance analyses. RESULTS: Data were obtained from 21 studies and included 159,352 patients diagnosed with CVD (38.1% female). Pooled HRs for all-cause and CVD mortality comparing the highest vs. lowest category of CRF were 0.42 (95% confidence interval (95%CI): 0.28-0.61) and 0.27 (95%CI: 0.16-0.48), respectively. Pooled HRs per 1 metabolic equivalent (1-MET) increment were significant for all-cause mortality (HR = 0.81; 95%CI: 0.74-0.88) but not for CVD mortality (HR = 0.75; 95%CI: 0.48-1.18). Coronary artery disease patients with high CRF had a lower risk of all-cause mortality (HR = 0.32; 95%CI: 0.26-0.41) than did their unfit counterparts. Each 1-MET increase was associated with lower all-cause mortality risk among coronary artery disease patients (HR = 0.83; 95%CI: 0.76-0.91) but not lower among those with heart failure (HR = 0.69; 95%CI: 0.36-1.32). CONCLUSION: A better CRF was associated with lower risk of all-cause mortality and CVD. This study supports the use of CRF as a powerful predictor of mortality in this population.
背景:心肺适能(CRF)与健康人群和某些临床人群的死亡率呈负相关,但在已确诊心血管疾病(CVD)的患者中,CRF 与全因和/或心血管疾病(CVD)死亡率之间的关联证据不足。本研究旨在量化这种关联。
方法:我们搜索了使用心肺运动试验测量 CVD 患者 CRF 并进行了至少 6 个月随访以检查全因和 CVD 死亡率的前瞻性队列研究。使用随机效应逆方差分析计算合并危险比(HR)。
结果:共获得 21 项研究的数据,纳入 159352 名诊断为 CVD(38.1%为女性)的患者。比较 CRF 最高与最低类别时的全因和 CVD 死亡率的合并 HR 分别为 0.42(95%置信区间[95%CI]:0.28-0.61)和 0.27(95%CI:0.16-0.48)。每增加 1 个代谢当量(1-MET)的合并 HR 与全因死亡率显著相关(HR=0.81;95%CI:0.74-0.88),但与 CVD 死亡率无关(HR=0.75;95%CI:0.48-1.18)。CRF 高的冠状动脉疾病患者的全因死亡率风险较低(HR=0.32;95%CI:0.26-0.41),而与之相比,功能不强者的全因死亡率风险较高。每增加 1-MET 与冠状动脉疾病患者的全因死亡率风险降低相关(HR=0.83;95%CI:0.76-0.91),但与心力衰竭患者无关(HR=0.69;95%CI:0.36-1.32)。
结论:更好的 CRF 与全因死亡率和 CVD 风险降低相关。本研究支持在该人群中使用 CRF 作为强有力的死亡率预测指标。
Cochrane Database Syst Rev. 2022-8-8
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2022-2-24
Cochrane Database Syst Rev. 2021-11-6
Cochrane Database Syst Rev. 2005-7-20
Cochrane Database Syst Rev. 2022-2-10
Cochrane Database Syst Rev. 2018-6-28
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2021-9-14
J Gerontol A Biol Sci Med Sci. 2025-5-5
BMC Sports Sci Med Rehabil. 2025-3-4
Int J Environ Res Public Health. 2024-11-23
J Am Coll Cardiol. 2019-5-7
Prog Cardiovasc Dis. 2019-1-9
J Am Coll Cardiol. 2018-12-18